Aquestive Therapeutics: My Biotech Investment Framework Now Requires Me To Downgrade AQST To Sell

Aquestive Therapeutics' stock was downgraded to 'sell' by an analyst due to concerns about the company's pipeline and competition in the market for its lead product, Libervant.

The analyst also expressed concerns about the company's financial position and cash runway.